Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01512316

Exploring Learning and Unlearning of Fear

The Effect of D-cycloserine on Fear Learning and Extinction

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The present study investigates the effect of d-cycloserine on learning and unlearning of fear in healthy humans and its underlying effect on the amygdala. As a second objective, the effect of genotype on fear learning will be studied.

Detailed description

A growing body of evidence suggests that the extinction of fear is mediated by the N-methyl-D-aspartate (NMDA) receptor activity in the basolateral amygdala. Intra-amygdala infusions of antagonists of this glutamate receptor in small animals (eg: rats, mice) have demonstrated a blockage of fear acquisition and extinction. Agonists, on the other hand, facilitate conditioned fear extinction. The animal studies are all based on the simple fear learning paradigm of conditioning. However, it is not clear that human anxiety disorders are based on prior conditioning encounter. Therefore it is important to disentangle the effect of DCS on acquisition and extinction in the context of a simple learning paradigm, particular its effect on the human amygdala.

Conditions

Interventions

TypeNameDescription
DRUGd-Cycloserine250mg, one dose, 2hrs prior to fMRI
DRUGLactose pillone dose, 2hrs prior to fmri
GENETICSaliva sampleBuccal cell material will be sampled from all participants on day3
OTHERFunctional neuroimaging (fMRI)

Timeline

First posted
2012-01-19
Last updated
2023-01-31

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01512316. Inclusion in this directory is not an endorsement.